AzTrials
AzTrials

AnxietyNCT07363915

Group Program vs Single-Session Depathologizing Intervention for Subthreshold Anxiety-Depression in Primary Care (Spain)

A study testing PADAP transdiagnostic CBT-based group program and Active Single-Session Depathologizing Intervention (SSDI) in people with Anxiety and Depressive Symptoms, run by University of Alcala at 1 site in Spain.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This study evaluated two psychological interventions for adults with mild to moderate subthreshold anxious-depressive symptoms in primary care in Spain. Participants referred by general practitioners were randomly assigned to either (1) PADAP, a manualized transdiagnostic group program delivered in 10 weekly 90-minute… Read more about this study

Who is it for?
Ages 18 to 65 years
Conditions the study is for
Anxiety, Depressive Symptoms, Anxiety Symptoms
What is being tested?
PADAP transdiagnostic CBT-based group program and Active Single-Session Depathologizing Intervention (SSDI)
Could I receive a placebo?
No, everyone receives an active treatment
How many people
136 participants
Where
1 siteSpain
Study dates
1 Feb 2021to 1 Sep 2023
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • 2. Referred from primary care by a general practitioner.
  • 3. Mild to moderate anxious-depressive symptoms based on the GP's clinical judgement during routine consultations, with or without psychotropic medication.
  • Exclusion Criteria: 1. Meeting DSM-IV Axis I diagnostic criteria based on the Structured Clinical Interview (SCID-I), assessed by two clinical resident psychologists.
  • 2. Receiving active mental health treatment (public or private).
  • 3. Current substance dependence (except nicotine).
  • 4. Organic, neurological, or cognitive disorder related to the symptoms.
  • 5. Language barriers that precluded participation or completion of assessments.

Who cannot join

None listed.

Trial locations and contacts

1 site in 1 country.

Spain1 site
  • Hospital Universitario Príncipe de Asturias (recruitment from 4 primary care centres), Spain

    Alcalá de Henares, Madrid, 28806

Other trials in Spain

About this study

Official title: A Randomized Controlled Trial Comparing a Manualized Group Program (PADAP) Versus an Active Single-Session Depathologizing Intervention (SSDI) for Subthreshold Anxious-Depressive Symptoms in Primary Care in Spain

This study evaluated two psychological interventions for adults with mild to moderate subthreshold anxious-depressive symptoms in primary care in Spain. Participants referred by general practitioners were randomly assigned to either (1) PADAP, a manualized transdiagnostic group program delivered in 10 weekly 90-minute sessions, or (2) a structured active single-session depathologizing intervention (SSDI), delivered individually in one 50-60-minute session.

The primary aim was to compare changes in depressive and anxiety symptoms from baseline to 12 months. Secondary aims included comparing primary care mental health-related consultations, psychotropic medication use, new contacts with mental health services, and perceived need for further mental health care during follow-up.

Read the detailed description

This was a prospective, parallel-group randomized controlled trial conducted in four primary care health centres in a large urban area in Spain. Adults aged 18-65 years referred by general practitioners for mild to moderate anxious-depressive symptoms were screened for eligibility. Exclusion criteria included meeting DSM-IV Axis I or II criteria based on the Structured Clinical Interview (SCID-I), current active treatment in mental health services, current substance dependence (except nicotine), organic/neurological/cognitive disorders related to symptoms, or language barriers. All participants provided written informed consent, and the study received ethics approval (reference 32/2019 [OE 18/2019]).

Eligible participants were allocated using a centralized, computerized randomization system to one of two intervention arms. Outcome assessment was performed by a blinded assessor. Participants assigned to SSDI received an individual, structured 50-60-minute session focused on empathic listening, contextualization and normalization of distress, narrative reframing, and activation of personal and social resources outside the healthcare system. Participants assigned to PADAP received a manualized, multimodal, transdiagnostic cognitive-behavioral group intervention delivered in 10 weekly 90-minute sessions covering psychoeducation about emotions and skills to manage anxiety, sadness, and anger.

Depressive symptoms were measured with the Beck Depression Inventory (BDI), and anxiety symptoms with the State-Trait Anxiety Inventory (STAI). Assessments were conducted at baseline and at 12 months. Data on primary care consultations for mental health reasons were extracted from electronic health records, along with information on psychotropic medication use and new contacts with mental health services during follow-up.

Being tested
PADAP transdiagnostic CBT-based group program, Active Single-Session Depathologizing Intervention (SSDI)
Keywords
Primary Care, Subthreshold Anxiety, Subthreshold Depression, Psychological Intervention, Cognitive Behavioral Therapy, Single-Session Intervention, Randomized Controlled Trial, Depathologizing
Medical subject headings
Anxiety Disorders, Depression

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • PADAP transdiagnostic CBT-based group programBehavioural

    Manualized, multimodal, transdiagnostic cognitive-behavioral group intervention delivered in 10 weekly sessions (90 minutes each) by trained clinical psychology residents. Content includes psychoeducation about emotions; anxiety management (physiological arousal management, cognitive restructuring, problem solving); sadness management (behavioral activation, increasing positive reinforcement); and anger management (anger regulation and assertiveness training).

  • Active Single-Session Depathologizing Intervention (SSDI)Behavioural

    Structured individual single-session intervention (50-60 minutes) delivered by trained clinical psychologists/clinical psychology residents. The session focuses on empathic listening and shared formulation; contextualization and normalization of distress; de-pathologizing explanations by challenging symptoms-as-disease narratives; narrative reframing; and activation of personal and social resources outside the healthcare system.

Study groups in NCT07363915
Study groupRoleWhat they receive
PADAP group program (10 sessions)Active comparatorManualized, multimodal, transdiagnostic cognitive-behavioral group intervention delivered in 10 weekly sessions (90 minutes each) by trained clinical psychology residents. Modules cover emotions (psychoeducation), anxiety (physiological arousal management, cognitive restructuring, problem solving), sadness (behavioral activation), and anger (anger regulation and assertiveness training).
Receives: Behavioral: PADAP transdiagnostic CBT-based group program
Single-session depathologizing intervention (SSDI)Active comparatorStructured individual single-session intervention (50-60 minutes) delivered by trained clinical psychology residents. The session focuses on empathic listening, shared formulation, contextualization and normalization of distress, narrative reframing (challenging symptoms-as-disease explanations), and activation of personal and social resources outside the healthcare system.
Receives: Behavioral: Active Single-Session Depathologizing Intervention (SSDI)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Anxiety symptoms (STAI-State and STAI-Trait total scores)

    State-Trait Anxiety Inventory (STAI), State and Trait subscales, total scores. Higher scores indicate greater anxiety symptom severity.

    Measured: Baseline and 12 months

  2. Depressive symptoms (BDI total score)

    Beck Depression Inventory (BDI), total score. Higher scores indicate greater depressive symptom severity.

    Measured: Baseline and 12 months

Secondary outcomes (4)
  1. GP mental health-related consultations (12 months pre vs 12 months post)

    Number of general practitioner (GP) consultations for mental health reasons extracted from electronic health records (AP Madrid/Horus/HCIS), measured for two periods: (1) the 12 months prior to baseline assessment, and (2) the 12 months following the intervention (post-baseline).

    Measured: 12 months before intervention and 12 months after intervention

  2. Psychotropic medication use (yes/no)

    Use of psychotropic medication (antidepressants, anxiolytics, both, or other mood-affecting medication). For analysis, coded as yes/no.

    Measured: Baseline and 12 months

  3. New contact with mental health services (yes/no)

    Recorded as yes if the participant requested or received psychological or psychiatric care (public or private) during follow-up.

    Measured: 12 months

  4. Perceived need for referral or additional care (yes/no)

    Based on the question: "Do you think you need to be referred to mental health services or receive any other additional intervention from us?". Coded as yes for affirmative responses and for participants who requested referral and were on a waiting list or under follow-up.

    Measured: 12 months after intervention

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted23 Jan 2026
  2. Study start1 Feb 2021
  3. Primary completion1 Sep 2023
  4. Study completion1 Sep 2023

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
Two-arm, parallel-group randomized controlled trial comparing PADAP group intervention versus a single-session depathologizing intervention (SSDI).
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
136 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07363915
Sponsor's protocol ID
CEIM32-2019-OE18-2019
Other IDs
UAH thesis 1147303, 32/2019 (OE 18/2019)
Status last verified
Jan 2026
First submitted
2 Jan 2026
Last updated
23 Jan 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: The datasets generated and/or analysed during the current study are not publicly available due to the risk of compromising participant privacy and because they include information derived from electronic health records, but are available from the corresponding author on reasonable request and subject to approval by the relevant data controller/health service.

Questions about this trial

What is this clinical trial studying?

A study testing PADAP transdiagnostic CBT-based group program and Active Single-Session Depathologizing Intervention (SSDI) in people with Anxiety and Depressive Symptoms, run by University of Alcala at 1 site in Spain.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 23 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Anxiety symptoms (STAI-State and STAI-Trait total scores) (time frame: Baseline and 12 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Jan 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in